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ABSTRACT 
Objective: A fast, specific, and sensitive high-performance liquid chromatographic method has been developed and validated for the quantitative 
determination of unchanged Ramipril (RAM) and Telmisartan (TEL) in animal plasma.  
Methods: Analytes were extracted from animal plasma, 250 µl of animal plasma sample were mixed with internal working standard (25 ngmL-1) with 
the further addition of chloroform (HPLC Grade, Merck). The clear organic layer was separated and reconstituted to 1 ml in mobile phase and analysed 
by HPLC. The method was validated and evaluated in terms of linearity, accuracy, precision, specificity, limit of detection and limit of quantitation.  
Results: Absorption maxima of TEL and RAM was found to be 270 and 273 nm respectively. TEL and RAM with their respective internal standards 
(I. S.) were found to be well separated from the co-eluted components and there were no interferences from the endogenous material. The limit of 
detection (LOD) and limit of quantitation (LOQ) were found to be 2.01±.05; 4.88±0.10 and 0.11 and 0.25 for TEL and RAM respectively on the basis 
of a signal to noise ratio. The ruggedness of the method at various parameters was found to be±1.94% and±1.02% for TEL and RAM respectively. 
The low values of %RSD (<2.0) for each of the drug proposed that during all deliberate variations, middle-quality control (MQC) was not affected 
and it was in accordance with that of actual.  
Conclusion: Thus developed High-Performance Liquid Chromatography (HPLC) method was found to be more accurate, precise, sensitive, selective 
and reproducible. 
Keywords: Ramipril, Telmisartan, Reverse Phase High-Performance Liquid Chromatography (RP-HPLC) and Validation 




Telmisartan (TEL) and Ramipril (RAM) are a safe and effective 
alternative for the treatment of hypertension. Moreover, due to its 
good tolerability, an increasing use of TEL in cardiovascular high risk 
animals can be anticipated. RAM is long-acting angiotensin-
converting-enzyme (ACE) inhibitor and known for its extensive tissue 
distribution. Chemically RAM is (1S,5S,7S)-8-((2S)-2-(((1S)-1-
ethoxycarbonyl-3-phenyl-propyl)amino) propanoyl)-8-azabicyclo 
(3.3.0) octane-7-carboxylic acid (fig. 1). RAM is a prodrug and non-
sulfhydryl angiotensin-converting enzyme (ACE) inhibitor with 
antihypertensive activity [1]. RAM is converted in the liver by de-
esterification into its active form ramiprilat, which inhibits ACE, 
thereby blocking the conversion of angiotensin I to angiotensin II. This 
abolishes the potent vasoconstrictive actions of angiotensin II and 
leads to vasodilatation. This agent also causes an increase in 
bradykinin levels and a decrease in angiotensin II-induced aldosterone 
secretion by the adrenal cortex, thereby promoting diuresis and 
natriuresis. TEL chemically 4’-[(1, 4’-Dimethyl-2’-propyl-[2, 6’-bi-1H-
benzimidazol]-1’-yl) methyl]-[1, 1’-biphenyl]-2-carboxylic acid (fig. 2), 
is a nonpeptide angiotensin-II receptor antagonist, which selectively 
and insurmountably inhibits angiotensin-II AT1 receptor subtype 
without affecting other systems involved in cardiovascular regulation 
[1]. TEL is an angiotensin receptor blocker (also called an angiotensin-
II receptor antagonist (AIIRA)). It is used to treat hypertension (high 
blood pressure). People with high blood pressure often do not feel 
unwell but, left untreated, high blood pressure can harm the heart and 
damage blood vessels. TEL work by blocking the effect of a chemical 
called angiotensin II found in bloodstream. Angiotensin II causes blood 
vessels to narrow, so by blocking this effect. TEL allows blood vessels 
to relax and widen. As this happens, the pressure within blood vessels 
is reduced. This also makes it easier for the heart to pump blood 
around Body. TEL is also used to help prevent heart attacks and 
strokes in people who may be at risk of these because of other medical 
conditions, such as diabetes. Literature survey revealed that 
telmisartan is not yet official in any of the pharmacopoeia. RAM is 
official in United States of pharmacopoeia (USP) and British 
Pharmacopoeia (BP) where high pressure liquid chromatography 
(HPLC) and potentiometric titration is the official method of analysis. 
There are numerous methods reported for estimation of these drugs 
alone as well as in combination with other drugs in pharmaceutical 
dosage forms [2-5] and/or in biological fluids. However, no method 
has been reported so far in the estimation of these two drugs 
simultaneously in combined dosage forms. A new RP-HPLC method for 
simultaneous estimation of TEL and RAM also has been developed. 
Although RP-HPLC method for simultaneous estimation of TEL and 
RAM and spectrophotometric method for estimation of TEL and RAM 
individual and in combination with other drug method has been 
developed to quantify TEL and RAM but no Spectrophotometric 
method has been developed for simultaneous estimation of TEL and 
RAM in combined dosage form.  
The aim of this study was to establish a simple, rapid, economic and 
accurate RP-HPLC method for the identification and measurement of 
TEL and RAM in plasma correlating the plasma concentration with 
dose and clinical picture of animals; beneficial to certain group of 
the population. The assay requires a small sample volume, involves a 
single step liquid-liquid extraction with a specific internal standard 
and a short chromatographic run. 
MATERIALS AND METHODS 
Chemicals and reagents 
TEL (fig. 1) and RAM (fig. 2) were gifted by Ipca Pharmaceutical Pvt. 
Ltd, Ratlam (Madhya Pradesh). All reagents used were of HPLC 
grade except acetic acid which was of analytical grade. Water was 
glass triple-distilled and further purified with a 0.44 µ filtration 
membranes using a vacuum pump. 
Equipments 
The HPLC system used consisted of Shimadzu LC-2010 AHT/ 
2010Cht, Kyoto, Japan, solvent delivery system, a system controller, 
an UV-Visible detector (PCB, LC2K-UV1) operated at wavelength 280 
nm, a degasser and data processor all of SHIMADZU. 
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Fig. 1: Structure of RAM 
 
 
Fig. 2: Structure of TEL 
 
Preparation of standard solutions of TEL  
One mg of pure TEL was weighed and transferred into a round 
bottom flask, 100 ml of methanol was added and sonicated for 15 
min for complete dissolution of the drug. Now, the solution was 
filtered through a 0.45 µm pore size nylon 66 membrane filters 
using a vacuum pump and further diluted using methanol to give 
stock solutions 10 µg/ml and stored at 4 °C. 
Method development for TEL 
Based on the solubility profile, pKa, polarity of a drug molecule and 
other factors like stability e. t. c, various mobile phase combination, 
flow rate, pH and ƛmax was selected and samples were run for 
optimum selection of chromatographic parameters to develop and 
validate the RP-HPLC method for estimation of TEL in biological 
matrices like plasma. The final set of chromatographic conditions 
was established using C18-ODS column (Thermo), 250 mm×4.6 mm 
I.D., 5 µm particle sizes which were protected by a guard column (1 
cm×4.0 mm I.D., 5 µm particle size). A mixture of methanol: 
Acetonitrile (70: 30) containing 0.1% Acetic Acid (pH adjusted to 2.5 
using 0.05 M KHPO4) was used as the mobile phase (isocratic 
separation). The detection wavelength was 270 nm and injection 
volume 10 µl. The mobile phase was filtered, degassed and pumped 
at a flow rate of 1.2 ml/min.  
Extraction of TEL from animal plasma 
Pharmacokinetic studies were carried out using healthy male Wistar 
rats weighing 240–270 g. The animals were housed in polyacrylic 
cages and maintained under standard laboratory conditions 
(temperature 25±2 °C) with dark and light cycles for at least seven 
days prior to the experiment and were given a commercial rat chow 
and water ad libitum. The experimental protocol was approved 
(IAEC/PSIT/1273/ac/2017) by the Institutional Animal Ethical 
Committee prior to the conduct of the animal experiments. After an 
overnight fast, the rats were given an oral administration of a mixture 
of RAM (1 mg/kg), and TEL (1 mg/kg) dissolved in 0.1% 
carboxymethylcellulose. The animals had free access to water after 4 h 
of the oral administration of drugs. The blood (~250 μl) was collected 
into heparinized tubes from the suborbital veniplex before 
administration and at 0.08, 0.15, 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 12.0, 
24.0, 36.0, 48.0, and 72.0 h after dosing. The plasma was immediately 
separated by centrifugation and stored frozen at −80 °C until analysis. 
250 µl of animal plasma sample was mixed with 50 µl of I. S. working 
standard (25 ng/ml) and are vortex-mixed for 5 min. Then 300 µl of 
chloroform [selected after extensive hit and trial extractions from 
solvents of different polarities] (HPLC Grade, Merck) was added and 
centrifuged at 10,000 rpm for 5 min. The clear organic layer was 
separated and reconstituted to 1 ml in the mobile phase, 100 µl was 
injected in the loop of Rheodyne valve for HPLC analysis. 
Preparation of stock solutions and working standards of RAM 
Various mobile phase combination, flow rate, pH and λmax was 
selected and samples were run for optimum selection of 
chromatographic parameters to develop and validate RP-HPLC 
method (as per the Food and Drug Administration (FDA) guidelines 
for bioanalytical method development and validation) for estimation 
of RAM in a biological matrix like plasma. The RP-HPLC method was 
developed and validated, eluents were monitored by absorbance at 
273 nm using a mixture of methanol: water (pH adjusted to 4.5 using 
dilute orthophosphoric acid) in the ratio of 72:28 (v/v) at a flow rate 
of 1.0 ml/min with C18 column. The detection wavelength was 273 
nm which was selected by analyzing overlain UV spectra of RAM of 
concentration 10 μg/ml each. 
Extraction of RAM from animal plasma 
Preparation of the working standard stock solution 
A primary stock solution (1 mg/ml) was prepared by dissolving 10 
mg of RAM in 10 ml of HPLC grade methanol. The stock solution was 
suitably diluted with HPLC grade methanol to obtain a working 
range of standard solutions. Plasma used in the study was isolated 
from blood by centrifugation at 10000 rpm for a period of 15 min at 
4 °C, using a centrifuge. 
Preparation of the working standard stock solution from plasma 
In 5 ml of a blood sample, 20 mg RAM and 10% of 0.2 ml 
trichloroacetic acid were added. The sample was centrifuged at 
3000 rpm for 35 min. To settle red blood cells at the bottom. The 
supernatant was separated and volume was made up to 10 ml to get 
the solution 1000 μg/ml of each drug. This solution was filtered 
through syringe filter of size 0.20μm. These solutions were diluted 
with mobile phase to get 200 μg/ml [RAM-100] stock solutions. 
Quality samples 
The quality control (QC) samples were prepared by pipetted 
appropriate aliquots from the standard stock solution into three 10 
ml volumetric flasks. The volume was made up to mark with the 
mobile phase to get concentrations of 1, 2 and 3 μg/ml. All samples 
were stored at refrigerated cold conditions (2-8 °C) and equilibrated 
to room temperature prior to use. 
Preparation of mobile phase  
For preparing a mobile phase, HPLC grade acetonitrile was filtered 
through a 0.20 μm membrane filter and subjected to degas in an 
ultrasonic bath for a period of 15 min and then 0.02M Potassium 
dihydrogen phosphate (pH 3.2) [80:20%V/V] was added. 
Dilutions 
Different concentrations of 0.5-5 μg/ml were prepared from the 
stock solution of the working standard. All the dilutions were 
prepared in Methanol. 
Preparation of sample stock solution 
Prior to sample analysis, 100 μl of each solution was extracted using 
300 μl of diethyl ether: dichloromethane (60:40% v/v) for protein 
precipitation. Further, each mixture was vortexes for a period of 5 
min in a vortex mixer with subsequent centrifugation at 10000 rpm, 
for a period of 10 min at 4 °C using a centrifuge. For each sample, an 
aliquot of a supernatant was isolated and subjected to dry. The 
residue was reconstituted in 100 μl of mobile phase and 
subsequently centrifuged at 10000 rpm for 10 min at 4 °C in a 
centrifuge. The supernatant was finally collected and directly 
injected into the HPLC system. This procedure was followed for all 
samples of the calibration curve and quality control (QC). 
Preparation of sample solution for analysis 
To plot the calibrations curve, different concentrations were 
prepared from the working stock solution individually of 
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concentration range 0.4-25.6 μg/ml for RAM and 5-250 ng/ml for 
TEL. 
Spiking of RAM and TEL in plasma for plasma calibration curve 
Drug-free plasma lots were removed from the deep freezer and 
allowed to attain room temperature. They were vortexes adequately 
before pipetting. 
Preparation of blank plasma samples 
Plasma isolated from rabbit blood by centrifugation at 10000 rpm 
for a period of 15 min at 4 °C, and then spiked 500 μl of blood 
plasma with 100 μL of dilutent methanol. 
Extraction technique 
Pretreatment of biological samples 
In bioanalysis, the method development step additionally requires the 
extraction trial in order to recover the analyte and internal standard 
from the highly complicated biological matrix. One should have 
knowledge about the nature of the drug, molecular weight, pKa, 
solubility, ionic character, partition coefficient. In initial stages of 
method development, our focus was to achieve the limit of 
quantitation (LOQ) level with precision and accuracy and to check for 
interference at the retention time of the analyte and internal standard. 
Validation parameters 
Linearity and range 
The linearity and range of the calibration curve were evaluated with 
nine calibration standards containing different concentrations of the 
respective drug (0.5-5 µg/ml). The study was repeated in triplicates 
to confirm reproducibility of results. The concentrations of the test 
samples were back-calculated using linear regression analysis. 
Selectivity 
Selectivity of developed method was assessed by comparing 
chromatograms of three different batches of blank plasma obtained 
from three individual rabbits with those of corresponding standard 
plasma samples. 
Accuracy and precision 
Intra-day precision and accuracy of the developed method were 
determined by analyzing six replicates of QC samples at three 
concentrations in a single sequence. Similarly, for inter-day 
precision and accuracy; six replicates QC samples at three 
concentrations were analyzed on three consecutive days. Accuracy 
of the method was determined by calculating percentage relative 
error (% RE) whereas the precision was determined by calculating 
percentage relative standard deviation (% RSD). 
Robustness 
The robustness of the developed method was studied by evaluating 
the effect of small but deliberate variations in chromatographic 
conditions. The parameters studied were flow rate and mobile phase 
composition. 
Recovery (extraction efficiency) 
To investigate extraction efficiency of the developed method, a set of 
samples (n=6) at each QC level was prepared by spiking drug into 
plasma samples and processed further (pre-extraction). Similarly, 
the second set of plasma samples was processed first and spiked 
post extraction at each QC levels. Extraction recovery for each 
analyte was determined by calculating the ratios of peak areas of the 
pre-extraction samples to those of the samples of post-extraction. 
Limits of detection (LOD) and limit of quantitation (LOQ) 
LOD and LOQ of the developed method were estimated on the basis 
of standard deviation and slope of the calibration curves. 
Method validation 
The proposed method was validated (using plasma matrix) as per 
FDA guidelines for bioanalytical method validation. 
Specificity and selectivity 
Specificity of the method was determined by analyzing six replicates 
of blank animal plasma obtained from six different sources. Each 
blank sample was tested for interference, and selectivity was 
ensured at the lower limit of quantification [LLQ]. The other possible 
interfering substances like co-administered drugs, blood 
components like hemoglobin etc, metabolites and excipients were 
also tested and it was found that no endogenous/external 
substances interfere with the assay.  
Accuracy and precision 
The accuracy and precision of the method can be determined by 
analyzing the spiked control samples with analyte concentrations 
around the lower limit of quantitation (LLQ), 2-5 times the LLQ, 0.5 
times the upper limit of quantitation (ULQ), ULQ and above ULQ. For 
acceptance criteria, accuracy should be within 85–115% of nominal 
concentration and for precision, the coefficient of variation (%CV) 
values should be<15% over the calibration range, except at the LLQ, 
where accuracy should be between 80-120% and %CV should not be 
more than 20%. Choosing three concentrations from above range, 
each spiked sample was analyzed at a minimum of 6 replicates for 
within run and between run accuracy and precision. The 
concentrations selected were 3, 10 and 30 ng/ml for plasma matrix. 
The results of accuracy and precision have been tabulated in results 
and discussion. 
Recovery 
Recovery experiments were performed by comparing the analytical 
results for extracted samples low. Medium and high concentration 
with un-extracted standards injected directly that represents 100% 
recovery. Each observation was determined in triplicate. The 
concentrations selected were 1, 2 and 3 µg/ml for plasma matrix. 
Recovery of internal standard (I. S.) was evaluated by comparing the 
mean peak areas of extracted samples to mean peak areas of reference 
solutions (un-extracted) of the same concentration (3 µg/ml).  
Linearity, the range of calibration curve 
Calibration curve was prepared in the same biological matrix as the 
samples in the intended study by spiking the matrix with known 
concentrations of the analyte including a blank sample (matrix 
sample without internal standard), a zero sample (matrix sample 
with internal standard), and six to eight non-zero samples covering 
the expected range, including LLQ.  
LOD and LLQ 
The LOD is the lowest concentration of an analyte in the sample that 
can be detected but not quantified under the stated experimental 
conditions. Blank samples were measured together with samples 
with concentrations of the analyte at the expected LOD. The signals 
of the blank and the analyte samples were compared and expressed 
as a signal-to-noise ratio. The LLQ is the lowest concentration of the 
analyte in the sample that can be measured with acceptable 
accuracy and precision under the stated experimental conditions. 
The signals of the blank samples were compared with the signals 
from samples which contain known low concentrations of the 
analyte. Next, a signal to noise ratio at which the analyte can be 
reliable quantified (3:1 for LOD and 10:1 for LLQ) was determined 
for plasma matrix. The procedure for LOD and LLQ was repeated 6 
times.  
Stability 
Stability of RAM and TEL in plasma samples was studied at three 
different stability conditions such as short-term, freeze-thaw, and 
long-term stability which were examined by replicate analysis of the 
low, medium and high concentration samples spiked in plasma 
matrices. Short term stability was carried out by keeping replicate 
samples for approximately 6 h. Freeze-thaw stability of samples was 
obtained over three freeze-thaw cycles, by thawing at room 
temperature for 2–3 h and refrozen for 12 h for each cycle. Long-
term stability of drugs in animal plasma was tested after storage at-
80 ° C for 30 d. For each concentration and storage condition, six 
replicates were analyzed in one set.  
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Ruggedness and robustness 
To evaluate ruggedness and robustness of methods, effects of 
variations of certain variables were investigated like pH, analyst, 
material, flow-rate, column temperature, mobile phase composition, 
and detection wavelength and extraction solutions. Results are 
shown in results and discussion [6]. 
Statistical analysis 
The mean plasma concentration was calculated using simple 
statistical application. Paired t-test was applied as a statistical tool 
for evaluation of differences in saliva vs plasma concentrations. A t-
test dependent correlation was used to compare correlation 
coefficient. Samples above the normal range and below the detection 
limit for HPLC assay were not included in the analysis. 
RESULTS AND DISCUSSION 
Selection of λmax 
The absorption of a standard solution of TEL and RAM was recorded 
in the wavelength range of 210-370 nm against methanol as blank. 
As showed in fig. 3 and 4, λmax was found to be 270 [7] and 273 nm 
respectively for TEL and RAM.  
 
 
Fig. 3: Ultraviolet spectroscopy of TEL at 270 nm 
 
Fig. 4: Ultraviolet spectroscopy of RAM at 273 nm 
 
Method development 
Based on the solubility profile, pKa, polarity of a drug molecule and 
other factors like stability etc, various mobile phase combinations, 
flow rate, pH and λmax was selected and samples were run for 
optimum selection of chromatographic parameters to develop and 
validate the RP-HPLC method for estimation of TEL and RAM in 
biological matrices like plasma [8]. All samples and solutions were 
prepared using solvent system (based on solubility profile) and 
biological matrix (extracted as discussed in methodology) as per the 
FDA guidelines for bioanalytical method development and 
validation. A detail account of various sets of chromatographic 
conditions (using a C18 column) for method development of TEL 
and RAM in Plasma is mentioned in table 1 and 2. The 
chromatograms for TEL [9] and RAM in Plasma are represented 
from fig. 5 and 6 respectively. 
 
Table 1: Method development of TEL in plasma matrix using RP-HPLC 









1 40 60 273 0.5 5(A) Peak was not well separated, LONG run time  
2 35 65 272 0.8 5(B) Peak shape for TEL was good but detector saturation was observed 
for TEL at 1 μl.  
3 30 70 270 1.0 5(C) Peak shape for TEL was good and retention time for TEL was 6.3.  
4 20 80 270 1.2 5(D) Animal Plasma Spiked with I. S.  
5 15 85 270 1.4 5(E) Mobile Phase  
6 10 90 270 1.4 5(F) blank plasma  
*ACN= Acetonitrile, **MeOH= Methanol  
 
Table 2: Method development of RAM in plasma matrix using RP-HPLC 






MeOH* H2O**  
1 90 10 273 0.5 6(A) Prolonged run time, peaks not resolved  
2 85 15 273 0.8 6(B) Peaks Overlap  
3 80 20 273 1.0 6(C) Tailing and long run time  
4 75 25 273 1.2 6(D) Slight Tailing  
5 72 28 273 1.0 6(E) Peak shape for RAM were good  
6 70 30 273 1.2 6(F) Mobile Phase  
**MeOH= Methanol, **H2O= water with dilute orthophodphoric acid (pH 4.5) 
 
Method validation 
TEL and naproxen (I. S.) and RAM and vasartan (I. S.) were well 
separated from the co-eluted components and there were no 
interferences from the endogenous material which was observed at 
retention time of both TEL and RAM with their respective I. S. Peaks 
of samples were of good quality and completely resolved from 
plasma components. The retention time of I. S. and TEL were found 
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to be 4.0 and 6.3 min, respectively, and the runtime was 8 min. 
Results revealed that the developed method was highly selective for 




Fig. 5: HPLC chromatogram for TEL and I. S. with different chromatographic conditions (as shown in table 1) (A) condition 1; (B) condition 
2; (C) condition 3, TEL spiked in blank animal plasma; (D) Condition 4; (E) Condition 5; (F) Condition 6 for mobile phase 
 
 
Fig. 6: HPLC chromatogram of RAM and I. S. with different chromatographic conditions (as shown in table 1) (A) Condition 1; (B) Condition 
2; (C) Condition 3; (D) Condition 4; (E) Condition 5 animal plasma spiked with I. S.; (F) Condition 6 for mobile phase 
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The accuracy and precision studies of TEL and RAM have been 
carried out by analyzing five determinations per concentration 
[three concentrations representing the entire range of the 
standard curve]. The results of accuracy were found to be in the 
range of 88.60% to 97.41% (table 3, 4). Therefore, based on the 
recovery data the estimation of related compounds that are 
prescribed in this report has been demonstrated to be accurate for 
the intended purpose and is adequate for routine analysis. The 
precision study has been done for intra and inters day variations 
for three consecutive days.  
The precision of the proposed method for RAM, expressed as % CV 
was determined by the analysis of three different concentrations. 
The intra-day precision was assessed from the results of five 
replicate analysis of quality control samples on the same day. The 
inter-day precision was determined from the same quality control 
samples analyzed on three consecutive days. 
  
Table 3: Validation of TEL 
S. 
No. 
















1 5 004.43±00.12 88.60 2.70 004.39±00.23 87.80 5.26 
2 25 022.81±00.99 91.24 4.34 023.46±01.29 93.84 5.49 
3 125 113.17±05.71 90.54 5.04 109.81±06.02 87.85 5.48 
*n=6 
 
Table 4: Validation of RAM 
Day Time % Concentration (mean±SD) RSD 
1 T1 91.23±2.9673 2.8541 
 T2 93.72±4.1569 4.2789 
 T3 97.41±2.2195 2.2786 
2 T1 93.72±4.0325 4.1677 
 T2 95.03±4.4897 4.6212 
 T3 90.20±1.5486 1.4987 
3 T1 95.13±2.0031 2.1852 
 T2 94.87±4.1025 4.2149 
 T3 91.20±3.4326 3.422 
*n=6 
 
The recovery of an analyte is the retention factor obtained from an 
amount of the analyte added to and extracted from plasma 
compared to same obtained for the true concentration of the quality 
control sample. Recovery experiments have been performed by 
comparing the analytical results for extracted samples at three 
concentrations as specified in quality control sample analysis with 
unexpected standards that represent 100% recovery. Over the 
concentrations studied, minimum extraction recovery of TEL and IS 
were found to be 86.96 and 91.40% respectively. While for RAM and 
IS were found to be 86.96 and 91.40% respectively (table 5) 
 
Table 5: Recovery studies of RAM and TEL with their respective IS in animal plasma 
S. No. Drugs Amount added Amount recovered (mean±SD) % recovery % CV 
1 RAM 1 0.98±00.01 98.00 1.02 
2  2 2.01±0.03 100.5 1.49 
3  3 2.99±0.04 99.67 1.34 
4 TEL 5 04.49±00.23 90.00 5.1 
5  25 21.87±01.13 87.48 5.2 
6  125 108.70±04.98 86.96 4.6 
*n=6 
 
The linearity of the method was evaluated by processing five-
point calibration curves. Good linearity was observed over the 
concentration range of 5-250 ng/ml and 0.5-5 μg/ml for TEL and 
RAM respectively. The peak area versus concentrations of drugs 
was plotted and a linear least square regression analysis was 
conducted to determine the slope, intercept and correlation 
coefficient (r2) to demonstrate the linearity of the method. The 
correlation coefficient (r2) in all cases was found to be>0.9987 
indicating a functional linear relationship between 
concentrations of analyte and the areas under the peak. The limit 
of detection and limit of quantitation was established by 
evaluating the signal to noise ratio of 3:1 and 10:1, respectively. 
The signals of the blank samples were compared with the 
samples containing known low concentrations of the analyte. 
The LOD (S: N; 3:1) and LOQ (S: N; 10:1) was found to be 
2.01±.05; 4.88±0.10 and 0.11 and 0.25 for TEL and RAM 
respectively on the basis of a signal to noise ratio. 
The ruggedness of the method at various parameters was found to 
be±1.94% and±1.02% for TEL and RAM respectively. For robustness 
of TEL and RAM, evident from ANOVA statistical test: the calculated F 
value was found to be less than tabulated F value (0.768637<4.06618 
and 0.6876<4.06618 respectively) indicated that method was robust 
enough for the analysis of TEL and RAM within the specified range of 
deviation in the experimental conditions. The low values of %RSD for 
each of the drug proposed that during all deliberate variations, 
middle-quality control (MQC) was not affected and it was in 
accordance with that of actual. Hence, the newly developed analytical 
method was considered to be robust [10]. 
Stability 
The stability of the drug-spiked at three QC levels evaluated for: 
short-term (6 h), freeze-thaw (3 cycles), and long-term (30 d). The 
results showed that the TEL was stable in animal plasma for about 
one month when stored in the frozen state (-80 °C). The accuracy 
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was greater than 89% and 87% in all cases for TEL and RAM 
respectively and within the predefined standard limits for 
bioanalytical methods (table 6). 
Clinical application for monitoring plasma levels of TEL 
The developed and validated method was applied for routine 
therapeutic monitoring of TEL and RAM in the plasma of 
hypertensive animals. The therapeutic range of both drugs was 
determined in plasma samples. 
In the present study, therapeutic range in which most of the 
animals (n=12) were stable was 5-250 ng/ml. A typical 
chromatogram obtained from animal plasma sample was shown 
in fig. 5(C). Amongst the 6 outliers, 3 animals were below range 
(<5 ng/ml) and 3 animals above range (>250 ng/ml). The 
outliers were either therapeutically compromised or showed an 
adverse effect associated with high concentration of drug-like 
sweating, flushing, fever, malaise, tinnitus, earache, and 
toothache etc. 
  
Table 6: Stability studies of TEL and RAM in animal plasma 
DRUG Conc. (ng/ml) Plasma conc. (mean±SD)* % Accuracy CV % 
Short term stability (6h) RT 
TEL 5 004.47±00.21 89.00 4.70 
 25 023.21±01.12 92.84 5.21 
 125 115.40±07.74 92.32 6.70 
Long term stability (-80 °C, 1 Mo) 
 5  04.43±00.38 89.00 8.58 
 25 23.17±02.14 92.68 9.24 
 125 107.11±09.31 85.68 8.69 
Freeze and thaw cycles 
 5 04.52±00.22 90.40 4.87 
 25 23.81±00.82 95.24 3.46 
 125 111.43±06.64 89.14 5.96 
Short term stability (6hr) RT 
RAM 1  1.09±0.1105 107 3.44 
 2  1.98±0.7821 101.30 7.72 
 3  2.67±1.2251 89.56 4.55 
Long term stability (-80 °C, 1 Mo) 
 1 1.85±0.1319 97.00 4.53 
 2 02.17±0.6718  97.70 6.87 
 3 2.92±1.4121 88.40 5.32 
Freeze and thaw cycles 
 1 0.977±00.22 90.40 4.87 
 2 2.67±0.2123 89.00 7.95 




Fig. 7: Typical chromatogram of RAM in animal plasma 
 
Clinical application for monitoring plasma levels of RAM 
Therapeutic range in which most of the animals (n=29) were stable 
was found to be 0.5-5 μg/ml. A typical chromatogram obtained from 
animal plasma sample was shown in fig. 7.  
Amongst the 10 outliers, three animals were below range (<0.4 μg/ml) 
and seven animals above range (>25.6 μg/ml). The outliers were 
either therapeutically compromised or showed an adverse effect 
associated with high concentration of drug-like hypotension, decrease 
urination, dry irritating cough, and high K+level. The regimen of these 
animals was changed later as per their clinical condition. 
Therapeutic drug monitoring of TEL and RAM 
Various mobile phase combination, flow rate, pH and λmax was 
selected and samples were run for optimum selection of 
chromatographic parameters to develop and validate RP-HPLC 
method (as per the FDA guidelines for bioanalytical method 
development and validation) for estimation of TEL and RAM in a 
biological matrix like plasma. 
Method validation 
TEL, RAM and I. S. were not well separated from the co-eluted 
components and there was interference from an endogenous 
material which was observed at a retention time of TEL, RAM and IS. 
There were no identifiable peaks, and not completely resolved from 
plasma components. 
Clinical application of the method 
The method was applied for routine estimation of RAM and TEL in 
hypertensive animals. A total of 10 animals were enrolled in the 
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study and further 6 included as per inclusion-exclusion criteria, out 
of which four animals completed the study. The method we applied 
for routine clinical monitoring of TEL and RAM in animals (fig. 8) 
showed that there were no specific peaks of the desired drugs. 
 
 
Fig. 8: Validation of developed method in animal plasma (TEL 40 mg+RAM 5 mg) 
 
But by monitoring these animals it was observed that combination 
therapy was not significantly better than alone TEL and RAM. 
Surprisingly, despite a reduction in systolic blood pressure of 2-3 
mmHg in the combination therapy as compared with the RAM 
group. The animals were clinically stable with a definite therapeutic 
level; below which the condition got worse and above which there 
was no therapeutic benefit but adverse effects precipitated. 
Developed methods reported the least interference of endogenous 
substances from plasma for separate estimation of TEL and RAM. 
Extraction recovery studies revealed excellent efficiency of extraction 
and precision studies showed that method was accurate and precise. 
We found a low LOD and LOQ which have proven sensitivity of the 
method to detect minute quantities of TEL and better accuracy and 
precision. Thus developed HPLC method was found to be more 
accurate, precise, sensitive, selective and reproducible. 
Although sometimes useful for proteinuria reduction and in the 
treatment of symptomatic animals with heart failure, the 
combination of an ACE inhibitor and an angiotensin receptor blocker 
(ARB) is not recommended for the treatment of hypertension. 
ACE/ARB combinations produce little additional BP reduction 
compared with monotherapy with either agent alone. In the ongoing 
TEL Alone and in Combination with RAM global endpoint trial, 
animals receiving the ACE inhibitor/ARB combination showed no 
improvement in cardiovascular endpoints despite additional blood 
pressure (BP) reduction averaging 2.4/1.4 mmHg. There were also 
more side effects with the combination than with individual agents. 
These combinations are classified as less effective. 
CONCLUSION 
In the present study, the attempt has been undertaken to develop the 
most simple, economical, sensitive and accurate analytical HPLC 
method for the simultaneous estimation of these drugs without their 
prior separation. The method gives good resolution between both the 
compounds with a short analysis time (<10 min). The method was 
validated and found to be simple, sensitive, accurate and precise. The 
developed methods have found to have the least interference of 
endogenous substances from plasma for separate estimation of TEL 
and RAM. Therefore, the proposed method can be used for routine 
analysis of RAM and TEL in their combined dosage form. 
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